Sterile Compounding Pharmacies Market Report 2025

The sterile compounding pharmacies market size has grown strongly in recent years. It will grow from $5.34 billion in 2024 to $5.63 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to patient safety concerns, a shift towards personalized medicine, home infusion therapies, clinical trials and investigational drugs, and support for rare diseases.

The sterile compounding pharmacies market size is expected to see strong growth in the next few years. It will grow to $7.3 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to a rise in chronic diseases, aging population and healthcare needs, drug shortages and supply chain disruptions, advancements in precision medicine, increased focus on patient-centric care. Major trends in the forecast period include automation and robotics integration, stringent regulatory compliance, personalized medicine and specialized compounds, shift to outsourced compounding services, and technological advances in aseptic techniques.

The anticipated surge in the demand for personalized medicine is poised to propel the growth of the sterile compounding pharmacies market in the future. Personalized medicine, which utilizes information about an individual's genes or proteins to prevent, diagnose, or treat diseases, is facilitated by sterile compounding pharmacies. These pharmacies play a crucial role in delivering personalized medications in a sterile environment, tailoring drugs based on individual needs to enhance treatment outcomes, patient satisfaction, and therapy adherence. Notably, the approval of 12 new personalized medicines in 2022, as reported by the Personalized Medicine Coalition, underscores the increasing prominence of personalized medicine. Hence, the escalating demand for personalized medicine is a driving force behind the growth of the sterile compounding pharmacies market.

The increasing aging population is significantly driving the growth of the sterile compounding pharmacies market in the future. An aging population refers to a scenario where the proportion of older individuals within a community rises over time. Sterile compounding pharmacies are essential in providing tailored medication solutions for this demographic by preparing medications in liquid, topical, or suppository forms, which facilitates easier administration. For example, in October 2022, the World Health Organization, a specialized health agency based in the US, reported that by 2030, 1 in 6 people globally will be 60 or older, and this figure will double to 2.1 billion individuals in this age group by 2050. Consequently, the growing aging population is expected to propel the sterile compounding pharmacies market.

The adoption of robotic automation emerges as a prominent trend in the sterile compounding pharmacies market. Major companies in the market focus on leveraging robotic automation to enhance their market position. For example, in March 2023, Omnicell Inc., a healthcare technology company, introduced the IVX Station, a robotic compounding technology designed for safe and efficient sterile compounding preparations using automation. This technology features an automated compounding process in an ISO Class 5 environment, incorporating continuous monitoring of temperature, humidity, and particles. The IVX Station prioritizes safety with advanced vision systems, gravimetric verification, auto-labeling, and automated application of tamper-evident syringe caps. Moreover, it offers scalability through a cloud-based formulation library, ensuring access to the latest authorized formulations for manufacturers.

Major companies in the sterile compounding pharmacies market adopt strategic acquisition and collaboration as part of their growth strategy. A strategic acquisition involves one company purchasing another or its assets to achieve long-term strategic objectives. In October 2023, Sharp, a pharmaceutical packaging company, acquired Berkshire Sterile Manufacturing (BSM) to enhance its capabilities in offering fully integrated small-to-medium scale sterile injectable services. The acquisition complements Sharp's services with BSM's expertise in sterile manufacturing and Contract Development and Manufacturing Organization (CDMO) services.

In January 2022, Revelation Pharma Corp, a compounding pharmacy company, acquired Innovation Compounding Inc. for an undisclosed amount. This strategic acquisition aligns with Revelation's goal of establishing a national network of 503A and 503B compounding pharmacies. Innovation Compounding Inc., a 503A compounding pharmacy, provides sterile and non-sterile compounded pharmaceuticals to patients in 49 states.

Major companies operating in the sterile compounding pharmacies market include B. Braun SE, PharMerica Corporation, Fagron Group BV, QuVa Pharma Inc., NewCo Pharma GmbH, Medisca, PharMEDium Healthcare Holdings Inc., Central Admixture Pharmacy Services (CAPS), SandsRx LLC, LeeSar Inc., Avella Specialty Pharmacy, Stokes Pharmacy Inc., Imprimis Pharmaceuticals Inc., Wells Pharmacy Network LLC, McGuff Compounding Pharmacy Services Inc., Potter's House Apothecary Inc., Pharos Innovations LLC, Triangle Compounding Pharmacy Inc., Valor Compounding Pharmacy Inc., Pace Pharmacy, PenCol Specialty Pharmacy LLC, Pavilion Compounding Pharmacy LLC, Olympia Pharmacy, MedisourceRx, Stat RX Pharmacy, Rx3 Compounding Pharmacy, Atlas Pharmaceuticals Co. Ltd., ReNue Rx, Premier Pharmacy Labs Inc., Absolute Pharmacy Inc.

North America was the dominant region in the sterile compounding pharmacies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sterile compounding pharmacies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sterile compounding pharmacies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Sterile compounding pharmacies are specialized facilities that prepare personalized medications in a sterile environment, tailoring medication to the specific needs of individuals. This approach proves beneficial for various reasons, including patient intolerance to standard commercial doses or specific components. Compounding in a sterile environment enables patients to receive drugs with customized doses and formulations, excluding non-essential and undesirable components.

The primary products in sterile compounding pharmacies include injectables, nasal, ocular, and otic formulations. Injectables are pharmacological substances or drugs intended for injection into the body using a needle and syringe. Sterile compounding pharmacies offer production services such as customization, patient-specific dosing, and elimination of intolerable components, ensuring the safety, sterility, and quality of injectable medications tailored to individual patient requirements. These injectables find application in various therapeutic areas, including hormone replacement therapy, pain management, dermatology, oncology, hematology, dental, among others. Administration routes include intravenous, intramuscular, and subcutaneous, catering to diverse end-users such as adults, pediatrics, geriatrics, and veterinary applications.

The sterile compounding pharmacies market research report is one of a series of new reports that provides sterile compounding pharmacies market statistics, including sterile compounding pharmacies industry global market size, regional shares, competitors with a sterile compounding pharmacies market share, detailed sterile compounding pharmacies market segments, market trends and opportunities, and any further data you may need to thrive in the sterile compounding pharmacies industry. This sterile compounding pharmacies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sterile compounding pharmacies market consists of sales of injectable drugs and infusions created in an environment free from microorganisms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.